- Home
- SONN vs REVB Comparison
SONN vs REVB Comparison
Compare SONN & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- REVB
- Stock Information
- Founded
- SONN N/A
- REVB 2020
- Country
- SONN United States
- REVB United States
- Employees
- SONN N/A
- REVB N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- SONN Health Care
- REVB Health Care
- Exchange
- SONN Nasdaq
- REVB Nasdaq
- Market Cap
- SONN 4.6M
- REVB 2.8M
- IPO Year
- SONN N/A
- REVB N/A
- Fundamental
- Price
- SONN $1.29
- REVB $3.10
- Analyst Decision
- SONN Strong Buy
- REVB
- Analyst Count
- SONN 2
- REVB 0
- Target Price
- SONN $38.00
- REVB N/A
- AVG Volume (30 Days)
- SONN 31.6K
- REVB 54.4K
- Earning Date
- SONN 05-16-2025
- REVB 05-13-2025
- Dividend Yield
- SONN N/A
- REVB N/A
- EPS Growth
- SONN N/A
- REVB N/A
- EPS
- SONN N/A
- REVB N/A
- Revenue
- SONN $1,000,000.00
- REVB N/A
- Revenue This Year
- SONN $5,376.22
- REVB N/A
- Revenue Next Year
- SONN N/A
- REVB N/A
- P/E Ratio
- SONN N/A
- REVB N/A
- Revenue Growth
- SONN 674.14
- REVB N/A
- 52 Week Low
- SONN $1.10
- REVB $2.36
- 52 Week High
- SONN $16.00
- REVB $60.80
- Technical
- Relative Strength Index (RSI)
- SONN 45.29
- REVB 51.92
- Support Level
- SONN $1.30
- REVB $2.79
- Resistance Level
- SONN $1.37
- REVB $3.09
- Average True Range (ATR)
- SONN 0.10
- REVB 0.24
- MACD
- SONN -0.01
- REVB 0.02
- Stochastic Oscillator
- SONN 22.58
- REVB 38.82
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).